This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Heyland, D. K. Articles by Wischmeyer, P. Search for Related Content PubMed PubMed Citation Articles by Heyland, D. K. Articles by Wischmeyer, P. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Antioxidants Hazardous Substances DB SELENIUM COMPOUNDS SELENIUM, ELEMENTAL Social Bookmarking                         What's this?

Optimizing the Dose of Glutamine Dipeptides and Antioxidants in Critically Ill Patients: A Phase I Dose-Finding Study

Daren K. Heyland, MD, MSc^*, Rupinder Dhaliwalm, RD^*, Andrew Day, MSc^*, John Drover, MD^*, Helene Cote, PhD and Paul Wischmeyer, MD

From the ^* Kingston General Hospital/Queen's University, Kingston, Ontario, Canada; the University of British Columbia, and the University of Colorado Health Science Center, Denver, Colorado

Correspondence: Daren K. Heyland, Kingston General Hospital/Queen's University, 76 Stuart Street, Kingston, Ontario, Canada K7L 2V7. Electronic mail may be sent to dkh2{at}post.queensu.ca.

Background: Supplementation with glutamine and antioxidants may be associated with an improvement in clinical outcomes, but the optimal dose of these substrates is unknown. The purpose of this study was to determine the safety of high doses of glutamine combined with antioxidants in critically ill patients. Methods: We conducted a single-center, open-label, dose-escalating clinical trial. Mechanically ventilated adult patients with clinical evidence of hypoperfusion were sequentially enrolled to 1 of 5 groups. Group 1 (n = 30): no supplementation; group 2 (n = 7): 0.35 g/kg/d of glutamine IV; group 3 (n = 7): same as group 2 plus 15 g/d of glutamine and 150 µg of selenium enterally; group 4 (n = 7): same as group 2 plus 30 g/d of glutamine and 300 µg of selenium enterally; and group 5 (n = 7): same as group 4 plus an additional 500 µg of selenium IV. After enrollment, nutrients were started as soon as possible. All patients were fed enterally according to clinical practice guidelines. Results: The primary outcomes for this study were change in sequential organ function assessment (SOFA) score and safety parameters. Secondary outcomes included whole blood glutathione (GSH), thiobarbituric acid reactive substances (TBARS), and blood cells' mitochondrial DNA/nuclear DNA ratio (RATIO). There were no adverse events attributable to the study nutrients, and the maximum and SOFA did not differ across groups. In group 2, a significant decrease in GSH levels was observed (p = .03). With subsequent groups, the slopes straighten out and the p values are no longer significant, suggesting a greater preservation of GSH levels with escalating doses. In group 2, the slope of the line representing TBARS was horizontal. With subsequent groups, the slopes decrease, and by group 5, this decrease reaches statistical significance (p = .03), suggesting a greater reduction in oxidative stress with the higher doses in group 5. The difference in slopes across all groups describing the mitochondrial RATIO is statistically significant (p = .001), again suggesting that, with higher doses, there is increased mitochondrial function. Conclusions: The doses of glutamine and antioxidants tested in this study seem to be safe and may have positive effects on some mechanistic endpoints. A larger trial will be necessary to confirm their therapeutic effects.

Journal of Parenteral and Enteral Nutrition, Vol. 31, No. 2, 109-118 (2007)
DOI: 10.1177/0148607107031002109


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Coeffier, S. Claeyssens, S. Lecleire, J. Leblond, A. Coquard, C. Bole-Feysot, A. Lavoinne, P. Ducrotte, and P. Dechelotte Combined enteral infusion of glutamine, carbohydrates, and antioxidants modulates gut protein metabolism in humans Am. J. Clinical Nutrition, November 1, 2008; 88(5): 1284 - 1290. [Abstract] [Full Text] [PDF]

				J. Wernerman Clinical Use of Glutamine Supplementation J. Nutr., October 1, 2008; 138(10): 2040S - 2044S. [Abstract] [Full Text] [PDF]

				M. M. Berger Zinc: A Key Pharmaconutrient in Critically Ill Patients? JPEN J Parenter Enteral Nutr, September 1, 2008; 32(5): 582 - 584. [Full Text] [PDF]

				D. K. Heyland, N. Jones, N. Z. Cvijanovich, and H. Wong Zinc Supplementation in Critically Ill Patients: A Key Pharmaconutrient? JPEN J Parenter Enteral Nutr, September 1, 2008; 32(5): 509 - 519. [Abstract] [Full Text] [PDF]

				A. Thomson The Enteral vs Parenteral Nutrition Debate Revisited JPEN J Parenter Enteral Nutr, July 1, 2008; 32(4): 474 - 481. [Abstract] [Full Text] [PDF]

				P. Wischmeyer Research and Advocacy in Nutrition Therapy: Our Specialty Needs You JPEN J Parenter Enteral Nutr, March 1, 2008; 32(2): 210 - 212. [Full Text] [PDF]

				R. Thibault, S. Welch, N. Mauras, B. Sager, A. Altomare, M. Haymond, and D. Darmaun Corticosteroids increase glutamine utilization in human splanchnic bed Am J Physiol Gastrointest Liver Physiol, February 1, 2008; 294(2): G548 - G553. [Abstract] [Full Text] [PDF]